- US-listed companies
- COSCIENS Biopharma Inc.
- Income statement
COSCIENS Biopharma Inc. (CSCID) Income statement
Market cap
$36.82M
P/E ratio
| 2017/12 | 2018/12 | 2019/12 | 2020/12 | 2021/12 | 2022/12 | 2023/12 | 2024/12 | 2025/12 | |
| Revenue | 1 | 27 | 1 | 4 | 5 | 6 | 4 | 10 | 7 |
| Revenue growth (%) | - | ||||||||
| Gross profit | - | 25 | - | - | - | - | - | 5 | 3 |
| Gross margin (%) | - | - | - | - | - | - | |||
| Research & development | 11 | 3 | 2 | 2 | 7 | 13 | 14 | 8 | 3 |
| Selling, general & administrative | - | - | - | - | - | - | - | 10 | 10 |
| Operating margin (%) | |||||||||
| Operating income | -23 | 10 | -10 | -6 | -9 | -24 | -18 | -18 | -11 |
| Income before tax | -20 | 10 | -6 | -5 | -8 | -23 | -17 | -15 | -10 |
| Pretax margin (%) | -2,196.6 | 35.9 | -1,171.1 | -129.3 | -161.2 | -403 | -368 | -158.8 | -138 |
| Net income | -17 | 4 | -6 | -5 | -8 | -23 | -17 | -15 | -10 |
| Net income margin (%) | |||||||||
| EBITDA | - | - | |||||||
| EBITDA margin (%) | - | - |